The Latest Breaking News from Tilray Brands

Tilray reported a positive update for its chemo-related drug.

The cannabis industry is rapidly growing, but will Canadian players be able to keep up?

Despite significant growth in recent years driven by increased legalization, the cannabis industry took a hit last year amid economic and industry-wide headwinds, including stubborn supply gluts. Furthermore, the industry will likely remain under pressure this year due to economic challenges. Hence, it could be wise to avoid fundamentally weak…

Mad Money host Jim Cramer said last week during a Lightning Round segment that now is a good time to invest in Tilray.

Canadian marijuana giant Tilray Brands, Inc. (NASDAQ: TLRY) (TSX:TLRY) reported Friday financial results for the first fiscal quarter ended August 31, 2022, with net revenue of $153.2 million, which compares to revenue of $168.02 million for the same period last year.

 

Tilray Brands, Inc. (NASDAQ: TLRY) (TSX:TLRY) net revenue grew 8% to $153.3 million during the fourth quarter 2022, from $142.2 million in the prior year quarter.

Tilray Brands, Inc. (NASDAQ: TLRY) (TSX:TLRY) has closed its acquisition from HT Investments MA LLC (“HTI”) of the secured convertible note issued by HEXO Corp. (NASDAQ: HEXO

US jobs report for June is scheduled for release at 8:30 a.m. ET. Analysts expect a 270,000 rise for nonfarm payrolls in June, compared with a better-than-expected 390,000 growth in May. Investors, meanwhile, focused on some notable insider trades.